recommeded site for you
harry uptodate
Neurology Science
Skin Care and Treatment
Clinical Diagnose
Medical Study
Liver Health Center
Kedokteran Umum
Information
Harry Mulyono

medical information up to date

Tuesday, December 30, 2008

ALCOHOL USE DISORDERS

ALCOHOL USE DISORDERS - Geninne Zinner, RNCS, ANP
BASICS
DESCRIPTION
• Any pattern of alcohol use causing significant physical, mental, or social dysfunction; key features are tolerance, withdrawal, and persistent use despite problems.
• Alcohol abuse: Maladaptive pattern of alcohol use manifested by 1 (or more) of
- Failure to fulfill obligations at work, school, or home
- Recurrent use in hazardous situations
- Recurrent alcohol-related legal problems
- Continued use despite related social or interpersonal problems
• Alcohol dependence: Maladaptive pattern of use manifested by 3 (or more) of the following
- Tolerance
- Withdrawal
- Using more than intended
- Persistent desire or attempts to cut down/stop
- Significant amount of time obtaining, using, or recovering from alcohol
- Social, occupational, or recreational activities sacrificed for alcohol use
- Continued use despite physical or psychological problems
• National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria for "at risk" drinking: Men >14 drinks a week, or >4 per occasion. Women: >7 drinks a week, or >3 per occasion.
• System(s) Affected: Nervous; Gastrointestinal
• Synonym(s): Alcoholism; Alcohol abuse; Alcohol dependence
ALERT
Geriatric Considerations
• Common in elderly; less likely to report problem. May exacerbate normal age-related cognitive deficits and disabilities.
• Multiple drug interactions
• Signs and symptoms may be different or attributed to chronic medical problem or dementia.
• Assessment tools may be inappropriate.
Pediatric Considerations
• Children of alcoholics at high risk
• In 2004, 28% of persons 12-20 years reported use in past month, 1 in 5 binge drink; binge drinkers are 7 more likely to report illicit drug use.
• Negative effect on maturation and development
• Early drinkers are 4 times more likely to develop a problem than those who begin >21.
• Depression, suicidal or disorderly behavior, family disruption, violence or destruction of property, poor school or work performance, sexual promiscuity, social immaturity, lack of interests, isolation, moodiness
Pregnancy Considerations
• Alcohol is teratogenic, especially during the 1st trimester; women should abstain during conception.
• 10-50% of children born to women who are heavy drinkers will have fetal alcohol syndrome.
• Women experience harmful effects at lower levels, and are less likely to report problems.
GENERAL PREVENTION
Counsel with family history and risk factors.
EPIDEMIOLOGY
• Predominant age: 18-25, but all ages affected
• Predominant sex: Male > Female (3:1)
Prevalence
• Lifetime prevalence: 13.6%
• 20% in primary care setting
• 48.2% of 21-year-olds in the US reported binge drinking in 2004.
RISK FACTORS
Family history, depression (40% with comorbid alcohol abuse), anxiety, other substance abuse, tobacco, male gender, low socioeconomic status, unemployment, peer/social approval, family dysfunction or trauma, PTSD, antisocial personality disorder, bipolar disorder, eating disorders, criminal involvement
Genetics
50-60% of risk is genetic.
PATHOPHYSIOLOGY
• Alcohol is a central nervous system depressant by facilitating -aminobutyric acid (GABA) inhibition and blocking N-methyl-D-aspartate receptors.
• Once tolerance has occurred, abrupt withdrawal results in hyperexcitability of these pathways.
ETIOLOGY
Multifactorial: Genetic, environment, psychosocial
ASSOCIATED CONDITIONS
• Cardiomyopathy
• Atrial fibrillation
• Hypertension
• PUD/gastritis
• Cirrhosis
• Fatty liver
• Cholelithiasis
• Hepatitis
• Diabetes mellitus
• Pancreatitis
• Malnutrition
• Upper GI malignancies
• Peripheral neuropathy
• Seizures
• Abuse
• Violence
• Trauma (falls, MVAs)


DIAGNOSIS
SIGNS AND SYMPTOMS
• Behavioral
- Anxiety, depression, insomnia;
- Visual, auditory, tactile hallucinations 12-72 hours after last drink
- Psychological and social dysfunction marital problems
- Social isolation/withdrawal
- Domestic violence
- Alcohol-related legal problems
- Repeated attempts to stop/reduce
- Loss of interest in nondrinking activities
- Employment problems (tardiness, absenteeism, decreased productivity, interpersonal problems, frequent job loss)
- Blackouts
- Complaints about alcohol-related behavior
- Frequent trauma, MVAs, ED visits.
• Physical
- Anorexia
- Nausea, vomiting
- Abdominal pain
- Palpitations
- Headache
- Impotence
- Menstrual irregularities
- Infertility
Physical Exam
• General: Fever, agitation, diaphoresis
• HEENT: Plethoric, rhinophyma, poor oral hygiene, oropharyngeal malignancies
• Cardiovascular: Hypertension, dilated cardiomyopathy, tachycardia
• Respiratory: Aspiration pneumonia
• Gastrointestinal: Stigmata of chronic liver disease, peptic ulcer disease, pancreatitis, esophageal malignancies, varices
• Genitourinary: Testicular atrophy
• Musculoskeletal: Unhealed fractures, myopathy, osteopenia, bone marrow suppression
• Neurologic: Tremors, cognitive deficits (e.g., memory impairment), peripheral neuropathy, Wernicke-Korsakoff syndrome, grand mal seizures 2-48 hours after last drink, delirium tremens (DTs) begin 48-72 hours after last drink
• Endocrine/metabolic: Hyperlipidemias, cushingoid appearance, gynecomastia
• Dermatologic: Burns (e.g., cigarettes), bruises, poor hygiene, palmar erythema, spider telangiectasias, caput medusa, jaundice
• Physical exam may be completely normal
• Withdrawal symptoms begin 4-12 hours after alcohol is stopped/reduced; peak in intensity on day 2 of abstinence; and are mostly resolved by 4th or 5th day
TESTS
• CAGE Questionnaire: (Cut down, Annoyed, Guilty, and Eye opener): More than 2 "yes" answers is 74-89% sensitive, 79-95% specific for alcohol use disorder; less sensitive for early problem drinking, or heavy drinking (1)[A]
• Alcohol Use Disorders Identification Test: 10 items, if >4: 70-92% sensitive (1)[A]
• "Had 5 or more drinks on any 1 occasion in last 3 months" sensitive screen for problem drinking
Lab
• Blood alcohol concentration
- >100 mg/dL in outpatient setting
- >150 mg/dL without obvious signs of intoxication
- >300 mg/dL at any time
• Levels suggestive if increased
- AST/ALT ratio >2.0
- -Glutamyl transferase (GGT)
- Mean corpuscular volume
- Prothrombin time
- Uric acid
- Triglycerides
- Cholesterol (total)
• Often decreased
- Calcium, magnesium, potassium, phosphorus
- Blood urea nitrogen (BUN)
- Hemoglobin, hematocrit
- Platelet count
- Serum protein, albumin
Imaging
• Radiograph: Multiple old rib fractures
• CT scan, MRI of brain: Cortical atrophy, lesions in thalamic nucleus and basal forebrain
Pathological Findings
• Liver: Inflammation or fatty infiltration (alcoholic hepatitis), periportal fibrosis (alcoholic cirrhosis occurs in only 10-20% of alcoholics)
• Gastric mucosa: Inflammation, ulceration
• Pancreas: Inflammation, liquefaction necrosis
• Heart: Dilated cardiomyopathy
• Immune system: Decreased granulocytes
• Endocrine organs: Elevated cortisol levels, testicular atrophy, decreased female hormones
• Brain: Cortical atrophy, enlarged ventricles
DIFFERENTIAL DIAGNOSIS
• Other substance use disorders
• Depression
• Dementia
• Cerebellar ataxia
• CVA
• Benign essential tremor
• Seizure disorder
• Hypoglycemia
• Diabetic ketoacidosis
• Viral hepatitis
TREATMENT
PRE-HOSPITAL
• Assess medical and psychiatric condition.
• Assess severity of withdrawal.
STABILIZATION
• Airways, breathing, circulation
• Short-acting benzodiazepine for seizure
• Correct electrolyte imbalances, acidosis
GENERAL MEASURES
• Brief interventions by primary care physicians are highly effective for problem drinking (1)[A].
• Involve family, if feasible.
• Treat comorbid problems (sleep, anxiety, etc.); use caution if prescribing medications with cross-tolerance to alcohol (benzodiazepine).
Activity
Fall preventions or restrictions if delirious
Nursing
• Frequent vital signs during acute withdrawal
• Clinical Institute Withdrawal Assessment Scale for Alcohol (CIWA-Ar) very helpful (2,3)[A].
IV Fluids
Maintain fluids during withdrawal.
MEDICATION (DRUGS)
First Line
• Symptom-triggered regimens (benzodiazepine given only when CIWA-Ar score > 8) result in less total medication given and shorter duration of treatment than fixed-dose regimens (2,3)[A].
• In fixed-dose regimens, 1st dose of benzodiazepine should achieve sedation without respiratory compromise; drugs then are tapered daily as long as withdrawal symptoms are stable; CIWA-Ar is often used to guide dosing.
• Benzodiazepines reduce incidence of DTs and seizures (2,3)[A].
- Chlordiazepoxide 50-100 mg PO/IM q6-8h, then taper (2-4)[A]
- Diazepam 5-20 mg q6-8h (2-4)[A]
- Lorazepam 1-4 mg q2-6h (2,3)[A]; in elderly, severe liver disease, or IV drip
- Phenobarbital 60-120 mg q6-8h (4)[B] may be safer during pregnancy.
- Carbamazepine 200 mg PO q.i.d., then taper over 5-7 days (efficacious for mild-moderate withdrawal, and is less sedating) (2)[A].
• Adjuncts to detoxification
- -Blockers for tachycardia or comorbid coronary artery disease (3)[B]
- Clonidine 0.1-0.2 mg PO t.i.d. for autonomic hyperactivity (3,4)[C]
- Antipsychotics for psychosis, agitation; haloperidol lowers seizure threshold (3)[C]
• Adjuncts to rehabilitation
- Naltrexone 50-100 mg PO daily, or 380 mg IM once every 4 weeks: Opiate antagonist reduces craving and chance relapse (5)[A].
- Acamprosate (Campral) 666 mg PO t.i.d. beginning after completion of withdrawal; reduces relapse of drinking (5)[A]
- Topiramate (Topamax) 25-300 mg PO daily or divided b.i.d.; enhances abstinence (3)[B]
• Supplements to all
- Thiamine 100 mg daily (1st dose IV prior to glucose to avoid Wernicke encephalopathy)
- Folic acid 1 mg daily
- Multivitamin daily
- Magnesium sulfate 1 g IM/IV q4-6h (if history of DTs or seizure) (2)[C]
• Contraindications
- Naltrexone: Pregnancy, hepatitis, hepatic failure. Monitor liver function tests.
• Precautions: Organic pain, organic brain syndromes
• Significant possible interactions: Alcohol, sedatives, hypnotics
Second Line
• Anticonvulsants gabapentin (Neurontin) and vigabatrin (Sabril) studied for detoxification (3)[B]
• Disulfiram 250-500 mg PO daily: Unproven efficacy; may provide psychologic deterrent
• Selective serotonin reuptake inhibitors (SSRIs) may be beneficial if comorbid depression exists.
FOLLOW-UP
DISPOSITION
Admission Criteria
Severe withdrawal symptoms (CIWA-Ar >14), prior DTs, withdrawal seizures, suicidal ideation or psychiatric symptoms, obstacles to follow-up, pregnancy, unstable living situation
Issues for Referral
Addiction specialist: 12-step or long-term program
PROGNOSIS
• Chronic relapsing disease; mortality rate > twice general population, death 10-15 years earlier
• Abstinence benefits survival, mental health, family, employment
• 12-step programs, cognitive-behavior and motivational therapies are effective during 1st year following treatment (1)[B].
COMPLICATIONS
• Cirrhosis
• GI malignancies
• Neuropathy
• Dementia
• Wernicke-Korsakoff syndrome
• CVA
• Ketoacidosis
• Infection
• Relapse
• Depression
• Suicide
• Trauma
PATIENT MONITORING
• Outpatient detoxification: Daily visits
• Early outpatient rehabilitation: Weekly visits
• Detoxification alone is not sufficient.
REFERENCES
1. Enoch MA, Goldman D. Problem drinking and alcoholism: Diagnosis and treatment. Amer Fam Phys. 2002;65:441-448.
2. Asplund CA, Aaronson JW, Aaronson HE. Three regimens for alcohol withdrawal and detoxification. J Fam Pract. 2004;53:545-554.
3. Bayard M, McIntyre J, Hill KR, et al. Alcohol withdrawal syndrome. Amer Fam Phys. 2004;69(pt 6):1443-1450.
4. Kosten TR, O'Connor PG. Management of drug and alcohol withdrawal. N Engl J Med. 2003;348:1786-1795.
5. Saitz R. Clinical practice. Unhealthy alcohol use. N Engl J Med. 2005;352-396.
6. Williams SH. Medications for treating alcohol dependence. Amer Fam Phys. 2005;72(pt 9):1775-1780.
ADDITIONAL READING
• Substance Abuse and Mental Health Services Administration. (NSDUH series H-27, DHHS Publication No. SMA 05-4061). 2005. (http://oas.samhsa.gov/prevalence.htm)
• National Institute on Alcohol Abuse and Alcoholism: (NIH Publication No. 00-1583). 2000. (http://pubs.niaaa.nih.gov/publications/10report/intro.pdf)
• National Council on Alcoholism and Drug Dependence. NCADD Fact Sheet. Available online: ncadd.org/pubs/fsproblems.html

No comments:

Post a Comment